UNI-MB - logo
UMNIK - logo
 

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources UM. For full access, REGISTER.

1 2 3 4 5
hits: 122
1.
  • Activity and safety of brig... Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
    Gettinger, Scott N, Dr; Bazhenova, Lyudmila A, Prof; Langer, Corey J, Prof ... The lancet oncology, 12/2016, Volume: 17, Issue: 12
    Journal Article
    Peer reviewed

    Summary Background Anaplastic lymphoma kinase ( ALK ) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with ...
Full text
2.
  • Genetic alterations in sign... Genetic alterations in signaling pathways in melanoma
    Haluska, Frank G; Tsao, Hensin; Wu, Helen ... Clinical cancer research, 2006-Apr-01, Volume: 12, Issue: 7 Pt 2
    Journal Article
    Peer reviewed
    Open access

    Alterations in the RAS signaling cascade are almost uniformly present in melanoma. RAS itself is only infrequently mutated in melanoma although downstream of RAS lie BRAF on the mitogen-activated ...
Full text

PDF
3.
  • Ponatinib in refractory Philadelphia chromosome-positive leukemias
    Cortes, Jorge E; Kantarjian, Hagop; Shah, Neil P ... The New England journal of medicine, 11/2012, Volume: 367, Issue: 22
    Journal Article
    Peer reviewed
    Open access

    Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by ...
Full text

PDF
4.
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch, Thomas J; Bell, Daphne W; Sordella, Raffaella ... The New England journal of medicine, 05/2004, Volume: 350, Issue: 21
    Journal Article
    Peer reviewed
    Open access

    Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of ...
Full text

PDF
5.
  • Ponatinib versus imatinib f... Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
    Lipton, Jeffrey H, Prof; Chuah, Charles, MD; Guerci-Bresler, Agnès, MD ... The lancet oncology, 05/2016, Volume: 17, Issue: 5
    Journal Article
    Peer reviewed

    Summary Background Ponatinib has shown potent activity against chronic myeloid leukaemia that is resistant to available treatment, although it is associated with arterial occlusion. We investigated ...
Full text
6.
  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
    Kim, Dong-Wan; Tiseo, Marcello; Ahn, Myung-Ju ... Journal of clinical oncology, 2017-Aug-01, Volume: 35, Issue: 22
    Journal Article
    Peer reviewed
    Open access

    Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated ...
Full text

PDF
7.
  • Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
    Oza, Amit M; Pignata, Sandro; Poveda, Andres ... Journal of clinical oncology, 2015-Nov-01, Volume: 33, Issue: 31
    Journal Article
    Peer reviewed

    The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR) pathway is an important target, and mTOR ...
Full text
8.
  • Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
    Demetri, George D; Chawla, Sant P; Ray-Coquard, Isabelle ... Journal of clinical oncology, 07/2013, Volume: 31, Issue: 19
    Journal Article
    Peer reviewed

    Aberrant mammalian target of rapamycin (mTOR) signaling is common in sarcomas and other malignancies. Drug resistance and toxicities often limit benefits of systemic chemotherapy used to treat ...
Full text
9.
  • Ponatinib efficacy and safe... Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
    Cortes, Jorge E.; Kim, Dong-Wook; Pinilla-Ibarz, Javier ... Blood, 07/2018, Volume: 132, Issue: 4
    Journal Article
    Peer reviewed
    Open access

    Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I. The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ...
Full text

PDF
10.
  • Genetic Interaction Between... Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
    Tsao, Hensin; Yang, Guang; Goel, Vikas ... Journal of investigative dermatology, 02/2004, Volume: 122, Issue: 2
    Journal Article
    Peer reviewed
    Open access

    Extant evidence implicates growth factor signaling in the pathogenesis of many tumor types, including cutaneous melanoma. Recently, reciprocal activating mutations of NRAS and BRAF were found in ...
Full text

PDF
1 2 3 4 5
hits: 122

Load filters